Considering that the availability, specificity, and biological activity of TGFβ1 are normally controlled by numerous interactions with membrane‐bound proteins,16 short peptides that mimic the binding domain of TGFβ1 and are able to efficiently activate the TGFβRII on target cells might represent novel therapeutic tools for treating allergies. The gene discussed is TGFB1; the disease is Allergy.